In the production of adult fixed-dose combination film-coated tablets for tuberculosis, rifampicin is typically blended with isoniazid, pyrazinamide, and ethambutol hydrochloride at ratios including the four-drug 150 mg/75 mg/400 mg/275 mg formulation. The crystalline API shows poor flow and low bulk density, and direct compression is rarely used because segregation occurs during hopper feeding on high-speed rotary presses. Wet granulation with aqueous or hydroalcoholic binder solutions remains the standard route, but the hydrazone structure of rifampicin requires close control of granulate pH and drying temperature. A high-shear granulation process records impeller amperage and chopper load as indirect endpoint measures, while final residual moisture is held between 1.5% and 2.5% by loss on drying per USP 731. Overdrying below 1.0% water produces brittle granules with friability above 1.0%, and overgranulation above 3.0% water increases lower punch sticking on rotary presses. The compression stage must demonstrate content uniformity according to USP 905 and dissolution according to USP 711; because isoniazid accelerates rifampicin degradation in acidic media, dissolution is conducted in 0.1 N hydrochloric acid and in pH 6.8 phosphate buffer to detect release-related degradation. The film coating system is generally an aqueous HPMC-based barrier applied in a perforated pan coater at inlet air temperatures below 70°C; higher temperatures darken the tablet surface and increase rifampicin-related substances. Polymorphic identity of the incoming API is checked by X-ray powder diffraction according to USP 941 or Ph. Eur. 2.9.33, because changes in polymorph ratios alter intrinsic dissolution. Tablet hardness is maintained between 90 N and 150 N for deep-seal aluminium blister packaging; lower hardness causes breakage during transport, while higher hardness reduces disintegration in acid. The WHO Prequalification Team and ICH Q6A require demonstration of dissolution profile similarity when formulation composition changes exceed the Level 2 range, and production-scale batch records typically include in-process checks for moisture, granule particle size, and coating weight gain.

What Limits Direct Encapsulation of Rifampicin in Hard Gelatin Capsules?

Direct encapsulation of rifampicin in hard gelatin capsules is limited by electrostatic build-up, low bulk density, and flow-driven segregation. On a dosator-type capsule filler, the powder bed collapses at speeds above 6,000 capsules per hour, leading to weight variation outside the 5% acceptance band; on tamping-pin machines, tamping forces above 150 N per pin produce dense plugs that delay disintegration and dissolution. The cohesion arises from the fine fraction of the API and can be reduced by dry granulation with microcrystalline cellulose, croscarmellose sodium, and colloidal silicon dioxide. The granulated blend is sieved through a 0.8 mm screen, and the fraction below 75 µm is controlled by air-jet sieving to less than 20% to avoid segregation. Capsule shell moisture is a critical boundary because gelatin cross-linking can occur when residual water in the shell interacts with reactive rifampicin degradation products; desiccant protection in HDPE bottles is required for tropical stability zones. Dissolution testing uses USP Apparatus 2 at 50 rpm in 900 mL of 0.1 N hydrochloric acid, with acceptance at Q 80% in 45 minutes. Content uniformity is assessed per USP 905, and residual water in the finished capsule is measured by Karl Fischer titration per USP 921. Endotoxin control for hospital unit-dose use follows Ph. Eur. 5.1.10, and batch records include in-process checks of lock length, capsule weight, and visual shell defects per 21 CFR 211.110.

In oral granule production for reconstitutable paediatric suspensions, rifampicin is usually dispersed rather than dissolved in the dry matrix. The granulation process is designed to embed the API in a protective saccharide or sugar-free carrier so that the reconstituted suspension remains dispersible and redispersible. If a sugar-based vehicle is used, the residual moisture in the final granules must be kept below 2.0% because free water promotes hydrolysis and acid-catalysed degradation of rifampicin in the presence of sugar impurities. Fluid bed top-spray granulation is conducted at inlet air temperatures of 55°C to 65°C and product temperatures below 45°C; higher product temperatures darken the granules and increase total related substances above the 1.5% threshold. A suspending agent such as xanthan gum or hydroxyethylcellulose is added as an external phase after drying, not inside the wet granulation step, because high-shear wet massing can destroy the polymer network. The dry granules are filled into amber HDPE bottles with silica gel canisters and induction-seal liners. The reconstituted suspension is assigned a short in-use shelf life because rifampicin degrades in aqueous solution and forms insoluble degradation products; pharmacists must label the suspension with an in-use period and require shaking before administration. Dissolution testing on reconstituted granules is performed in pH 6.8 phosphate buffer to mimic the intestinal environment, while content uniformity is evaluated on the dry granule blend according to USP 905. Water activity is monitored in addition to Karl Fischer moisture according to USP 921, because water activity below 0.60 is a more direct control for microbial and chemical stability in powder fills.

Lyophilized Injection Cake Architecture and pH Drift on Reconstitution

Parenteral rifampicin is supplied as a sterile lyophilized powder or cake for preparation of an intravenous infusion. The API is converted to a water-soluble salt before lyophilization or during sterile formulation, because the free acid has limited aqueous solubility for direct injection. The freeze-drying cycle is intended to produce a robust cake with residual moisture below 3.0% and a glassy matrix that resists collapse during shipping. Primary drying shelf temperature is held below the collapse temperature; excursions produce visible meltback, shrinkage, and elongated reconstitution time. The lyophilized cake is reconstituted with 10 mL of water for injection, yielding a basic concentrate that must be further diluted into 0.9% sodium chloride injection or 5% dextrose injection before administration. Precipitation of rifampicin free acid can occur if the final admixture pH drifts below 6.0, so infusion solutions with low pH are avoided. Particulate matter in the reconstituted solution is controlled by light obscuration according to USP 788, and bacterial endotoxins are tested per Ph. Eur. 2.6.14. Sterile filling is performed in Grade A laminar airflow under ISO 14644-1 Class 5 conditions, with media fills and filter integrity tests required by 21 CFR 211.113. Container closure integrity is verified under 21 CFR 211.94. Elemental impurities are controlled according to ICH Q3D, and residual solvents are monitored per ICH Q3C by gas chromatographic methods. Light protection is maintained throughout because rifampicin is photodegradable; amber vials or secondary cartons are standard. The diluted admixture is administered over 30 minutes to 120 minutes depending on the dose, and the prepared infusion bag is not stored for extended periods unless stability data support such storage.

Dispersible tablet formulations of rifampicin for paediatric tuberculosis place simultaneous demands on disintegration, taste masking, and dissolution. The tablet must disintegrate in 10 mL of water within 3 minutes to permit accurate dosing in children who cannot swallow whole tablets. Superdisintegrants such as crospovidone or croscarmellose sodium are used at 3% to 6% of the core weight; higher levels reduce hardness below 40 N and increase friability above 1.0% on rotary presses. Dry granulation by roller compaction is preferred when isoniazid and pyrazinamide are present in the same blend, because wet granulation can dissolve these drugs and redeposit them as hardened agglomerates. Ribbon density is maintained between 1.1 g/cm³ and 1.3 g/cm³; ribbon densities above 1.3 g/cm³ slow rifampicin release due to work-hardening of the API-rich matrix. Dissolution testing in 0.1 N hydrochloric acid at 30 minutes and in pH 6.8 phosphate buffer at 45 minutes is used to detect coating or matrix effects. The tablets must meet a dissolution criterion of not less than 80% of labelled rifampicin released within 45 minutes, consistent with WHO paediatric FDC guidance. Taste masking is accomplished by fluid bed coating with amino methacrylate copolymer, but the coating thickness must be controlled so that disintegration remains below 3 minutes. Packaging uses aluminium-aluminium blister with sealed desiccant rather than PVC/PVDC, because dispersible dosage forms are more hygroscopic and rifampicin is hydrolysis-sensitive. Content uniformity is verified according to USP 905, and granule size distribution is measured by sieve analysis per USP 786 before compression.

When Rifampicin Is Wet-Granulated with Isoniazid and Pyrazinamide

When rifampicin is wet-granulated with isoniazid and pyrazinamide in a single high-shear mixer, the main process conflict is the acid-catalysed hydrolysis of the rifampicin hydrazone side chain. Water or water-alcohol granulating fluids can dissolve enough isoniazid to lower the local pH and accelerate rifampicin degradation at the granule surface. A buffer such as sodium citrate dihydrate at 1% to 2% of the dry blend is sometimes added to keep the wet mass pH above 5.0. The degradation reaction is also heat-driven; the time from liquid addition to the start of drying is limited to 30 minutes in production batches. High-shear impeller speed is held between 100 rpm and 150 rpm, and the chopper is used in short pulses rather than continuously because frictional heat raises local product temperature. Fluid bed drying with inlet air above 70°C produces a red-brown residue on filter bags and can push total impurities above the 1.5% release limit. Many production sites therefore avoid aqueous wet granulation for rifampicin-isoniazid combinations and use non-aqueous granulation with isopropyl alcohol or dry granulation by roller compaction. The dried granules are milled through a 1.0 mm screen, and the fraction above 850 µm is minimized because rifampicin release from large granules is slower and less uniform. When these controls are absent, batch-to-batch dissolution variability increases due to non-uniform distribution of the API and surface degradation during drying. The finished blend is lubricated with magnesium stearate at 0.5% to 1.0%, added as the final blending step to avoid over-lubrication and dissolution slowdown.